Search This Blog

Sunday, September 17, 2017

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

THOUSAND OAKS, Calif.Sept. 15, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a new analysis of the cardiovascular outcomes study (FOURIER) demonstrated that lowering low-density lipoprotein cholesterol (LDL-C) levels with Repatha® (evolocumab) significantly and consistently reduced cardiovascular events in patients with and without diabetes at baseline.

http://investors.amgen.com/phoenix.zhtml?c=61656&p=RssLanding&cat=news&id=2300849

No comments:

Post a Comment